China’s Sinovac has reported positive Phase III data for its coronavirus vaccine, CoronaVac, with 50.65% overall efficacy after two weeks, following two doses.
Based on clinical trials taking place in Brazil and Turkey, results show the vaccine was 83.7% effective at preventing severe cases and 100% effective against hospitalization or death.
On Saturday, the Chinese regulator granted Sinovac emergency approval for the product, making it the second vaccine OK’d for general use in the country.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze